204 related articles for article (PubMed ID: 19121624)
1. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd).
Zahedi Avval F; Berndt C; Pramanik A; Holmgren A
Biochem Biophys Res Commun; 2009 Feb; 379(3):775-9. PubMed ID: 19121624
[TBL] [Abstract][Full Text] [Related]
2. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.
Hashemy SI; Ungerstedt JS; Zahedi Avval F; Holmgren A
J Biol Chem; 2006 Apr; 281(16):10691-7. PubMed ID: 16481328
[TBL] [Abstract][Full Text] [Related]
3. Motexafin gadolinium: a novel redox active drug for cancer therapy.
Magda D; Miller RA
Semin Cancer Biol; 2006 Dec; 16(6):466-76. PubMed ID: 17112739
[TBL] [Abstract][Full Text] [Related]
4. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines.
Lecane PS; Karaman MW; Sirisawad M; Naumovski L; Miller RA; Hacia JG; Magda D
Cancer Res; 2005 Dec; 65(24):11676-88. PubMed ID: 16357179
[TBL] [Abstract][Full Text] [Related]
5. Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.
Magda D; Lecane P; Miller RA; Lepp C; Miles D; Mesfin M; Biaglow JE; Ho VV; Chawannakul D; Nagpal S; Karaman MW; Hacia JG
Cancer Res; 2005 May; 65(9):3837-45. PubMed ID: 15867382
[TBL] [Abstract][Full Text] [Related]
6. Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities.
Evans JP; Xu F; Sirisawad M; Miller R; Naumovski L; de Montellano PR
Mol Pharmacol; 2007 Jan; 71(1):193-200. PubMed ID: 17018578
[TBL] [Abstract][Full Text] [Related]
7. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin.
Miller RA; Woodburn KW; Fan Q; Lee I; Miles D; Duran G; Sikic B; Magda D
Clin Cancer Res; 2001 Oct; 7(10):3215-21. PubMed ID: 11595717
[TBL] [Abstract][Full Text] [Related]
8. Theoretical studies on the mechanism of inhibition of Ribonucleotide Reductase by (E)-2'-Fluoromethylene-2'-deoxycitidine-5'-diphosphate.
Fernandes PA; Ramos MJ
J Am Chem Soc; 2003 May; 125(20):6311-22. PubMed ID: 12785865
[TBL] [Abstract][Full Text] [Related]
9. Modeling and Proposed Molecular Mechanism of Hydroxyurea Through Docking and Molecular Dynamic Simulation to Curtail the Action of Ribonucleotide Reductase.
Iman M; Khansefid Z; Davood A
Recent Pat Anticancer Drug Discov; 2016; 11(4):461-468. PubMed ID: 27670694
[TBL] [Abstract][Full Text] [Related]
10. More potent linear peptide inhibitors of mammalian ribonucleotide reductase.
Tan C; Gao Y; Kaur J; Cooperman BS
Bioorg Med Chem Lett; 2004 Nov; 14(21):5301-4. PubMed ID: 15454215
[TBL] [Abstract][Full Text] [Related]
11. A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicity.
Crona M; Codó P; Jonna VR; Hofer A; Fernandes AP; Tholander F
Mol Oncol; 2016 Nov; 10(9):1375-1386. PubMed ID: 27511871
[TBL] [Abstract][Full Text] [Related]
12. Theoretical study on the inhibition of ribonucleotide reductase by 2'-mercapto-2'-deoxyribonucleoside-5'-diphosphates.
Pereira S; Fernandes PA; Ramos MJ
J Am Chem Soc; 2005 Apr; 127(14):5174-9. PubMed ID: 15810852
[TBL] [Abstract][Full Text] [Related]
13. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
[TBL] [Abstract][Full Text] [Related]
15. The use of thiols by ribonucleotide reductase.
Holmgren A; Sengupta R
Free Radic Biol Med; 2010 Dec; 49(11):1617-28. PubMed ID: 20851762
[TBL] [Abstract][Full Text] [Related]
16. Enzyme ribonucleotide reductase: unraveling an enigmatic paradigm of enzyme inhibition by furanone derivatives.
Cerqueira NM; Fernandes PA; Ramos MJ
J Phys Chem B; 2006 Oct; 110(42):21272-81. PubMed ID: 17048956
[TBL] [Abstract][Full Text] [Related]
17. Ascorbate and endocytosed Motexafin gadolinium induce lysosomal rupture.
Berndt C; Kurz T; Bannenberg S; Jacob R; Holmgren A; Brunk UT
Cancer Lett; 2011 Aug; 307(2):119-23. PubMed ID: 21492999
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase inhibitors as anti-herpes agents.
Wnuk SF; Robins MJ
Antiviral Res; 2006 Sep; 71(2-3):122-6. PubMed ID: 16621038
[TBL] [Abstract][Full Text] [Related]
19. Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs.
Plamthottam S; Sun D; Van Valkenburgh J; Valenzuela J; Ruehle B; Steele D; Poddar S; Marshalik M; Hernandez S; Radu CG; Zink JI
J Biol Inorg Chem; 2019 Aug; 24(5):621-632. PubMed ID: 31250199
[TBL] [Abstract][Full Text] [Related]
20. The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, MDL 101,731.
Kanazawa J; Takahashi T; Akinaga S; Tamaoki T; Okabe M
Anticancer Drugs; 1998 Aug; 9(7):653-7. PubMed ID: 9773810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
